Literature DB >> 28814763

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

L Rasche1, S S Chavan1, O W Stephens1, P H Patel1, R Tytarenko1, C Ashby1, M Bauer1, C Stein1, S Deshpande1, C Wardell1, T Buzder1, G Molnar1, M Zangari1, F van Rhee1, S Thanendrarajan1, C Schinke1, J Epstein1, F E Davies1, B A Walker1, T Meissner2, B Barlogie1, G J Morgan1, N Weinhold3.   

Abstract

In multiple myeloma malignant plasma cells expand within the bone marrow. Since this site is well-perfused, a rapid dissemination of "fitter" clones may be anticipated. However, an imbalanced distribution of multiple myeloma is frequently observed in medical imaging. Here, we perform multi-region sequencing, including iliac crest and radiology-guided focal lesion specimens from 51 patients to gain insight into the spatial clonal architecture. We demonstrate spatial genomic heterogeneity in more than 75% of patients, including inactivation of CDKN2C and TP53, and mutations affecting mitogen-activated protein kinase genes. We show that the extent of spatial heterogeneity is positively associated with the size of biopsied focal lesions consistent with regional outgrowth of advanced clones. The results support a model for multiple myeloma progression with clonal sweeps in the early phase and regional evolution in advanced disease. We suggest that multi-region investigations are critical to understanding intra-patient heterogeneity and the evolutionary processes in multiple myeloma.In multiple myeloma, malignant cells expand within bone marrow. Here, the authors use multi-region sequencing in patient samples to analyse spatial clonal architecture and heterogeneity, providing novel insight into multiple myeloma progression and evolution.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28814763      PMCID: PMC5559527          DOI: 10.1038/s41467-017-00296-y

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  61 in total

1.  How I treat high-risk myeloma.

Authors:  Sagar Lonial; Lawrence H Boise; Jonathan Kaufman
Journal:  Blood       Date:  2015-08-13       Impact factor: 22.113

2.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

3.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

Review 4.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

5.  P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.

Authors:  Lucía López-Anglada; Norma C Gutiérrez; Juan L García; María V Mateos; Teresa Flores; Jesús F San Miguel
Journal:  Eur J Haematol       Date:  2009-12-14       Impact factor: 2.997

6.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

7.  Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution.

Authors:  Shaoping Ling; Zheng Hu; Zuyu Yang; Fang Yang; Yawei Li; Pei Lin; Ke Chen; Lili Dong; Lihua Cao; Yong Tao; Lingtong Hao; Qingjian Chen; Qiang Gong; Dafei Wu; Wenjie Li; Wenming Zhao; Xiuyun Tian; Chunyi Hao; Eric A Hungate; Daniel V T Catenacci; Richard R Hudson; Wen-Hsiung Li; Xuemei Lu; Chung-I Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-11       Impact factor: 11.205

8.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Authors:  Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal
Journal:  Science       Date:  2014-10-10       Impact factor: 47.728

9.  Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data.

Authors:  F Favero; T Joshi; A M Marquard; N J Birkbak; M Krzystanek; Q Li; Z Szallasi; A C Eklund
Journal:  Ann Oncol       Date:  2014-10-15       Impact factor: 32.976

10.  Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.

Authors:  Brian A Walker; Christopher P Wardell; Lorenzo Melchor; Annamaria Brioli; David C Johnson; Martin F Kaiser; Fabio Mirabella; Lucia Lopez-Corral; Sean Humphray; Lisa Murray; Mark Ross; David Bentley; Norma C Gutiérrez; Ramón Garcia-Sanz; Jesus San Miguel; Faith E Davies; David Gonzalez; Gareth J Morgan
Journal:  Leukemia       Date:  2013-07-02       Impact factor: 11.528

View more
  99 in total

Review 1.  [Pathogenesis of multiple myeloma].

Authors:  L Rasche; N Weinhold
Journal:  Internist (Berl)       Date:  2019-01       Impact factor: 0.743

2.  18F-FDG PET/CT in multiple myeloma: critical insights and future directions.

Authors:  Clément Bailly; Thomas Carlier; Bastien Jamet; Cyrille Touzeau; Philippe Moreau; Françoise Kraeber-Bodéré; Caroline Bodet-Milin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02-15       Impact factor: 9.236

3.  Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Authors:  Tilmann Bochtler; Maximilian Merz; Thomas Hielscher; Martin Granzow; Korbinian Hoffmann; Alwin Krämer; Marc-Steffen Raab; Jens Hillengass; Anja Seckinger; Christoph Kimmich; Tobias Dittrich; Carsten Müller-Tidow; Dirk Hose; Hartmut Goldschmidt; Ute Hegenbart; Anna Jauch; Stefan O Schönland
Journal:  Blood Adv       Date:  2018-10-23

Review 4.  Tracking myeloma tumor DNA in peripheral blood.

Authors:  Johannes M Waldschmidt; Tushara Vijaykumar; Birgit Knoechel; Jens G Lohr
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-14       Impact factor: 3.020

Review 5.  Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.

Authors:  Vidya C Sinha; Helen Piwnica-Worms
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

Review 6.  Molecular basis of clonal evolution in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2020-02-06       Impact factor: 2.490

Review 7.  Toward personalized treatment in multiple myeloma based on molecular characteristics.

Authors:  Charlotte Pawlyn; Faith E Davies
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

8.  Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias.

Authors:  Bernhard Gerber; Martina Manzoni; Valeria Spina; Alessio Bruscaggin; Marta Lionetti; Sonia Fabris; Marzia Barbieri; Gabriella Ciceri; Alessandra Pompa; Gabriela Forestieri; Erika Lerch; Paolo Servida; Francesco Bertoni; Emanuele Zucca; Michele Ghielmini; Agostino Cortelezzi; Franco Cavalli; Georg Stussi; Luca Baldini; Davide Rossi; Antonino Neri
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 9.941

Review 9.  Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.

Authors:  Johannes M Waldschmidt; Praveen Anand; Birgit Knoechel; Jens G Lohr
Journal:  Semin Hematol       Date:  2018-03-01       Impact factor: 3.851

10.  Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.

Authors:  Jayeeta Ghose; Domenico Viola; Cesar Terrazas; Enrico Caserta; Estelle Troadec; Jihane Khalife; Emine Gulsen Gunes; James Sanchez; Tinisha McDonald; Guido Marcucci; Balveen Kaur; Michael Rosenzweig; Jonathan Keats; Steven Rosen; Amrita Krishnan; Abhay R Satoskar; Craig C Hofmeister; Flavia Pichiorri
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.